| 发明名称 | Method for diagnosing a rhinovirus infection | ||
| 摘要 | The present invention relates to a pharmaceutical composition comprising at least one peptide consisting of a minimum of 8 and a maximum of 50 amino acid residues comprising amino acid residues 1 to 8 of a rhinovirus capsid protein selected from the group consisting of VP1, VP2, VP3 and VP4. | ||
| 申请公布号 | US9638694(B2) | 申请公布日期 | 2017.05.02 |
| 申请号 | US201013504766 | 申请日期 | 2010.11.02 |
| 申请人 | Viravaxx GmbH | 发明人 | Valenta Rudolf;Niespodziana Katarzyna;Edlmayr Johanna;Blaas Dieter;Niederberger-Leppin Verena;Papadopoulos Nikos;Popow-Kraupp Theresia |
| 分类号 | C12Q1/02;C12Q1/04;C12Q1/70;A61K39/12;G01N33/569 | 主分类号 | C12Q1/02 |
| 代理机构 | Nevrivy Patent Law Group P.L.L.C. | 代理人 | Nevrivy Patent Law Group P.L.L.C. |
| 主权项 | 1. A method for diagnosing in vitro a rhinovirus infection caused by at least one of rhinovirus strains 1B, 29, 47, 62, 79 and 89 in a mammal comprising the steps of: providing an antibody comprising sample of a mammal, contacting said sample with at least one peptide consisting of a minimum of 15 and a maximum of 50 amino acid residues comprising amino acid residues 1 to 15 of a rhinovirus VP1 capsid protein of rhinovirus strain 89, and diagnosing a rhinovirus infection when the binding of antibodies to said at least one peptide is detected. | ||
| 地址 | Vienna AT | ||